Genentech, Inc.

Leland Stanford Junior University

Bolt Biotherapeutics, Inc.

Magenta Therapeutics, Inc.

Audi Ag

Gerber Technology, Inc.

Sensei Biotherapeutics, Inc.

David Y Jackson

Daniel P Sutherlin

Edgar George Engleman

Arthur Lee

Shelley Erin Ackerman

Michael Nathaniel Alonso

Dean R Artis

Mark E Reynolds

Thomas E Rawson

James A Wells

Brian Salvatore Safina

Mark S Stanley

Justin A Kenkel

Edward Ha

Frederick C Sailes

Lewis J Gazzard

John P Burnier

Lars B Abrahmsen

Justin Wooyoung Lee

Johannes Schmid

James O'Brien

Tilo Koch

Anton Obermüller

Edward HyungSuk Ha

Kevin Armin Samii

James L Andrews

Edward Hyungsuk Ha

Scott M Frankel

Nathan Mitchell

Tobias Pfaff

Carlo Camporesi

David Klaus

Edith Arnold

Michael Shyh-Yen Ho

Tim Horenburg

Markus Hörwick

Uwe Koser

Joann M Um

Daniel Ram

David Macy

Edilson De Aguiar

Karen M Stritzinger

Joann Um

Provided herein are modified antibodies, compounds used to make them, and intermediates in their synthesis; compositions; formulations and methods, including methods of treating diseases, disorders or conditions, for example, cancer, in humans.

Modified antibodies and related compounds, compositions and methods of use

The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.

Antibody adjuvant conjugates

The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and 'Ab' is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

Immunoconjugates targeting HER2

Provided herein are antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.

Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use

An improved system to provide a clothing model in augmented reality and/or virtual reality is disclosed. In one embodiment, the system provides a fully simulated garment, on the user's device, in an augmented reality or virtual reality display. In one embodiment, the process uses a parameterized smart garment model which enables real-time interaction with the garment on a device such as a mobile phone or tablet, with limited memory and processing power. In one embodiment, the system permits nearly instantaneous alteration of garment sizes. Because the garment is modeled to accurately reflect physical details, the lay of the garment changes as the size of the garment or body changes.

Clothing model generation and display system

Modified antibodies and related compounds, compositions, and methods of use

Bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) are described. Pharmaceutical compositions comprising an effective amount of a 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders are described. Methods are described for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a 1,8 bis-naphthalimide compound.

Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use

A system for providing information to a vehicle occupant includes a haptic control element which is provided in the vehicle and is configured to generate a haptic signal. An electronic control unit is operatively connected to the haptic control element and activates the haptic control element in order to indicate with a haptic signal that information is available for retrieval.

System and method for providing information in a vehicle

The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.

Tyrosine derivatives

Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, Rto R, m and n are as defined herein. Compounds of the invention bind to &#x3b1;integrin receptors and thereby inhibit binding of ligands for &#x3b1;integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with &#x3b1;integrins or their ligands.

Integrin receptor inhibitors

The invention provides novel thiocarbamate alpha-4 inhibitors of the general formula (I) that are resistant to metabolism having improved half-life and/or clearance properties compared to corresponding carbamate compounds wherein substituents L, X, Y, Z, R&#x2013;R, m, n, o and p are as defined herein. Also provided are compositions comprising compounds of formula I and a carrier, diluent or excipient as well as methods of treating a disease or condition mediated by the binding interaction of alpha-4 integrins to its ligands such as inflammatory diseases.

Thiocarbamate inhibitors of alpha-4 integrins

Provided are compounds of formula (I)wherein A, Q, W, X, Y, Z, Rto R, m and n are as defined herein. Compounds of the invention bind to &#x3b1;integrin receptors and thereby inhibit binding of ligands for &#x3b1;integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with &#x3b1;integrins or their ligands.

Growing community of inventors

Belmont, CA, United States of America

David Y Jackson